Forthcoming Pharmacological Agents and Trials that Could Impact your Practice late this Decade

Monday, February 27, 2023

3:01 PM – 3:09 PM ET

Speaker(s)

C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

Disclosure(s):

C. Michael Gibson, MD: Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)